<qa>  What is the randomized, single-center, cross-over, comparative bioavailThis study is a randomized, single-center, cross-over, comparative bioavailability and adhesion study, comparing single administrations of a new scopolamine transdermal delivery system formulation to the current established reference transdermal delivery system in healthy adult participants. The study will consist of an ambulant screening day within 21 days prior to the first investigational medicinal product IMP administration at study Day 1 and two treatment periods. Each treatment period will consist of 4.5 days 108 hours of in-house confinement. 